Scinai Immunotherapeutics Faces Nasdaq Minimum Bid Price Notification

Scinai Immunotherapeutics Faces Nasdaq Notification

On March 16, 2026, Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company, announced that it has received an official notification from the Nasdaq Listing Qualifications Department. This notification pertains to the company's failure to meet Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). The notification indicates that Scinai's American Depositary Shares (ADSs) have traded below the $1.00 per share threshold for a duration of 30 consecutive business days.

Despite this notification, it is important to note that there is no immediate impact on the listing or trading of Scinai's ADSs on the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), Scinai has been granted a compliance period of 180 calendar days, which allows them until September 8, 2026, to regain compliance with the minimum bid price requirement. This window provides Scinai with an opportunity to take the necessary actions to lift the trading price of its ADSs above the required threshold.

The company has outlined that if, during this compliance period, the closing bid price of its ADSs reaches $1.00 or more for at least ten consecutive business days, Nasdaq will provide confirmation of compliance, effectively resolving the notification issue.

In response to this situation, Scinai is proactively monitoring the closing bid price of its ADSs and exploring various strategies to meet the Nasdaq minimum bid price requirement.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. specializes in the development of innovative immunology therapies. The company has a robust pipeline of therapeutic candidates, including those licensed from renowned institutions such as the Max Planck Society and PinCell S.r.l. Furthermore, Scinai operates a subsidiary, Scinai Biopharma Services Ltd., which functions as a contract development and manufacturing organization (CDMO), providing essential development and manufacturing services to other biotechnology and pharmaceutical companies.

Scinai is dedicated to advancing healthcare through its therapies and believes in the importance of compliance with all market requirements for its continued operation and growth within the biopharmaceutical sector.

With the challenges posed by maintaining NASDAQ listing standards, Scinai's management team remains optimistic about their path forward, leveraging their innovative research and development capabilities to support their compliance objectives.

For investors and stakeholders, it’s crucial to stay informed about Scinai’s performance and developments as the company navigates this compliance process and continues to drive its therapeutic innovations forward. Scinai encourages interested parties to visit their official website at www.scinai.com for regular updates and access to its investor relations resources.

Scinai Immunotherapeutics remains committed to meeting the expectations of its shareholders and working diligently to uphold its standing in the competitive biopharmaceutical landscape. As the September deadline approaches, the company is expected to implement all necessary measures to restore compliance and continue on its growth trajectory.